Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

SNSE
Sensei Biotherapeutics, Inc. Common Stock
stock NASDAQ

At Close
Nov 10, 2025 9:31:28 AM EST
9.20USD+4.190%(+0.37)12,576
0.00Bid   0.00Ask   0.00Spread
Pre-market
Nov 6, 2025 8:03:30 AM EST
8.34USD-5.549%(-0.49)0
After-hours
Nov 6, 2025 4:26:30 PM EST
9.03USD-3.319%(-0.31)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
10:37AM EST  Cambrian BioPharma Inc Purchases 50,000 Shares Of Sensei Biotherapeutics At Avg. Price $4.72/Share   Benzinga
Jan 6, 2022
08:45AM EST  Sensei Biotherapeutics Names Erin Colgan As CFO   Benzinga
08:00AM EST  Sensei Biotherapeutics Announces Executive Promotions   GlobeNewswire Inc
Dec 16, 2021
09:01AM EST  Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has won a Comparably award for 2021 Best CEOs.   GlobeNewswire Inc
Dec 14, 2021
08:22AM EST  The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks   Benzinga
Dec 13, 2021
04:03PM EST  Sensei Biotherapeutics Announces Addition To The Nasdaq Biotechnology Index   Benzinga
04:01PM EST  Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it was added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to market open on Monday, December 20, 2021.   GlobeNewswire Inc
Nov 19, 2021
04:02PM EST  Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced its participation in a fireside chat during the Piper Sandler 33rd Annual Virtual Healthcare conference being held from November 29 to December 2, 2021.   GlobeNewswire Inc
Nov 12, 2021
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:18AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:17AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:16AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:15AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:14AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:12AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:10AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:09AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:02AM EST  V-domain Ig-containing suppressor of T-cell activation (VISTA) is a novel immune checkpoint protein that has been recognized as an important potential immunotherapeutic target   GlobeNewswire Inc
Nov 9, 2021
11:47AM EST  Sensei Biotherapeutics Q3 EPS $(0.32) Up From $(3.00) YoY   Benzinga
08:55AM EST  - SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate fromTMAb platform -   GlobeNewswire Inc
Nov 3, 2021
09:23AM EDT  Sensei Biotherapeutics To Participate In The Berenberg Virtual U.S. CEO Conference On Tuesday, November 9, 2021   Benzinga
09:01AM EDT  Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, president and chief executive officer, will participate in a fireside chat at the Berenberg virtual U.S. CEO Conference on Tuesday, November 9 at 10:00 a.m. EST.   GlobeNewswire Inc
Oct 1, 2021
08:16AM EDT  Sensei Biotherapeutics To Present New Preclinical Data For SNS-101 At 36th Annual Meeting Of The Society For Immunotherapy Of Cancer Nov. 10-14   Benzinga
08:05AM EDT  Sensei Biotherapeutics to Present New Preclinical Data for   GlobeNewswire Inc
Aug 4, 2021
08:38AM EDT  Sensei Biotherapeutics Q2 EPS $(0.32) Up From $(3.02) YoY   Benzinga
07:49AM EDT  Sensei Biotherapeutics Q2 2021 EPS $(0.32) Vs $(3.02) YoY   Benzinga
07:45AM EDT  - Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model   GlobeNewswire Inc
Aug 2, 2021
08:01AM EDT  Sensei Biotherapeutics Appoints Kristian Humer to its Board of   GlobeNewswire Inc
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jul 1, 2021
10:11AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021   Benzinga
07:33AM EDT  Berenberg Downgrades Sensei Biotherapeutics to Hold, Announces $12 Price Target   Benzinga
Jun 30, 2021
07:29AM EDT  The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs   Benzinga
Jun 29, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021   Benzinga
08:17AM EDT  The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout   Benzinga
06:14AM EDT  Oppenheimer Downgrades Sensei Biotherapeutics to Perform   Benzinga
Jun 28, 2021
04:06PM EDT  Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs   Benzinga
04:05PM EDT  - Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs -   GlobeNewswire Inc
May 19, 2021
05:03PM EDT  Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated   GlobeNewswire Inc
May 18, 2021
07:44AM EDT  The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
07:46AM EDT  Sensei Biotherapeutics Q1 EPS $(0.42) Up From $(4.00) YoY   Benzinga
07:41AM EDT  - ImmunoPhage platform programs and the VISTA program continue to advance -   GlobeNewswire Inc
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 5, 2021
08:05AM EDT  Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and   GlobeNewswire Inc
Apr 5, 2021
08:12AM EDT  Sensei Biotherapeutics Appoints Jessie English To Its Board   RTTNews
08:00AM EDT  Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its   GlobeNewswire Inc
Mar 31, 2021
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
Mar 30, 2021
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
Mar 25, 2021
08:07AM EDT  Sensei Biotherapeutics Reports FY20 EPS $(12.53) Up From $(55.92) YoY   Benzinga
08:00AM EDT  -Successfully completed upsized IPO in February2021 raising approximately $152.6 million in gross proceeds   GlobeNewswire Inc
Mar 22, 2021
08:00AM EDT  Sensei Biotherapeutics Announces Inclusion in Russell 2000 Index   GlobeNewswire Inc
Mar 9, 2021
08:30AM EST  Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present at the Oppenheimer 31st Annual Virtual Healthcare Conference on Tuesday, March 16th, 2021 at 9:20 a.m. ET.   GlobeNewswire Inc
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
Mar 1, 2021
11:04AM EST  Oppenheimer Initiates Coverage On Sensei Biotherapeutics with Outperform Rating, Announces Price Target of $36   Benzinga
10:14AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021   Benzinga
06:07AM EST  Piper Sandler Initiates Coverage On Sensei Biotherapeutics with Overweight Rating, Announces Price Target of $25   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 26, 2021
08:17AM EST  The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida   Benzinga
Feb 10, 2021
04:55PM EST  Sensei Biotherapeutics Announces Closing of Initial Public Offering   GlobeNewswire Inc
Feb 9, 2021
11:08AM EST  companies and therapeutics to treat diseases of aging, coupled with a unique operational strategy   PR Newswire
Feb 4, 2021
12:04PM EST  Sensei Biotherapeutics Shares Open At $24.70; IPO Priced At $19/Share   Benzinga
Feb 3, 2021
10:05PM EST  Sensei Biotherapeutics Prices Upsized IPO Of 7 Mln Shares At $19.00/shr   RTTNews
08:44PM EST  Sensei Biotherapeutics Announces Pricing of Upsized Initial Public   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC